NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer

• DOI: 10.3892/ijo.2018.4426
• Publication Date: 2018-05-31T11:32:25Z
• Authors: Ting‑Ting Zhang; Ning Qu; Guo‑Hua Sun; Long Zhang; Yuan‑Jin Wang; Xiang‑Ming Mu; Wen‑Jun Wei; Yu‑Long Wang; Yu Wang; Qing‑Hai Ji; Yong‑Xue Zhu; Rong‑Liang Shi
• Keywords: neuregulin 1; Viability assay

Thyroid cancer is a common endocrine cancer, of which papillary thyroid (PTC) the most type. Neuregulin 1 (NRG1), glycoprotein mediating cell‑cell signaling, plays vital roles in cellular activities; however, its role PTC progression remains poorly understood. In this study, we performed immunohistochemistry 196 samples from patients and found that NRG1, potential prognostic marker highly expressed compared with adjacent normal tissues. Cell Counting kit‑8 (CCK‑8) clone formation assays indicated NRG1 essential for cell viability proliferation, probably by regulating redox homeostasis, was implied ROS generation analysis intracellular GSH activity assay. Western blot RT‑qPCR revealed regulates ERK pathway pivotal regulator status, nuclear factor E2‑related 2 (NRF2), maintains moderate reactive oxygen species (ROS) levels through set antioxidant response element (ARE)‑containing genes. The immunohistochemical scoring data 490 Cancer Genome Atlas (TCGA) reveled positive association between expression NRF2. Since presence homeostasis NRF2, protecting cells accumulation ROS‑induced death, may thus prove to be therapeutic target treatment cancer.